After Pfizer, Serum Institute of India seeks emergency use nod for its Covid-19 vaccine

After Pfizer India, Serum Institute of India has applied to Drugs Controller General of India (DCGI) seeking an emergency use authorisation for the Oxford COVID-19 vaccine in the country.

On Sunday, Pfizer India became the first pharmaceutical firm to approach the Drugs Controller General of India (DCGI) seeking an emergency use authorisation for its Covid-19 vaccine in the country.

Pune-based Serum Institute is conducting a phase-3 trial of its coronavirus vaccine called Covishield in different parts. In order to introduce an urgently needed vaccine against COVID-19 in India, SII, the world's largest vaccine manufacturer, has entered into a collaboration with the University of Oxford and Swedish pharma giant AstraZeneca to manufacture the vaccine.

As per the Indian Council of Medical Research (ICMR), Serum Institute has manufactured four crore doses of the vaccine under the at-risk manufacturing and stockpiling licence obtained from the DCGI.

Serum Institute of India applies to Drugs Controller General of India (DCGI) for emergency use authorisation for its Covishield vaccine: Sources#COVID19pic.twitter.com/bWEwarryd3

— ANI (@ANI) December 7, 2020